Evidence-Based Guideline for the management of osteoporosis in men
Fuggle, Nicholas R; Beaudart, Charlotte; Bruyère, Olivier; Abrahamsen, Bo; Al-Daghri, Nasser; Burlet, Nansa; Chandran, Manju; Rosa, Mario M; Cortet, Bernard; Demonceau, Céline; Dere, Willard; Halbout, Philippe; Hiligsmann, Mickaël; Kanis, John A; Kaufman, Jean-Marc; Kurth, Andreas; Lamy, Olivier; Laslop, Andrea; Maggi, Stefania; Matijevic, Radmila; McCloskey, Eugene; Mobasheri, Ali; Prieto Yerro, Maria C; Radermecker, Régis P; Sabico, Shaun; Al-Saleh, Yousef; Silverman, Stuart; Veronese, Nicola; Rizzoli, René; Cooper, Cyrus; Reginster, Jean-Yves; Harvey, Nicholas C (2024-03-14)
Springer
14.03.2024
Fuggle, N.R., Beaudart, C., Bruyère, O. et al. Evidence-Based Guideline for the management of osteoporosis in men. Nat Rev Rheumatol 20, 241–251 (2024). https://doi.org/10.1038/s41584-024-01094-9
https://rightsstatements.org/vocab/InC/1.0/
© Springer Nature Limited 2024. This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1038/s41584-024-01094-9
https://rightsstatements.org/vocab/InC/1.0/
© Springer Nature Limited 2024. This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1038/s41584-024-01094-9
https://rightsstatements.org/vocab/InC/1.0/
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:oulu-202406274974
https://urn.fi/URN:NBN:fi:oulu-202406274974
Tiivistelmä
Abstract
Historically, osteoporosis has been viewed as a disease of women, with research, trials of interventions and guidelines predominantly focused as such. It is apparent, however, that this condition causes a substantial health burden in men also, and that its assessment and management must ultimately be addressed across both sexes. In this article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents GRADE-assessed recommendations for the diagnosis, monitoring and treatment of osteoporosis in men. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its associated high fracture risk in men, covering disease burden, appropriate interpretation of bone densitometry (including the use of a female reference database for densitometric diagnosis in men) and absolute fracture risk, thresholds for treatment, and interventions that can be used therapeutically and their health economic evaluation. Future work should specifically address the efficacy of anti-osteoporosis medications, including denosumab and bone-forming therapies.
Historically, osteoporosis has been viewed as a disease of women, with research, trials of interventions and guidelines predominantly focused as such. It is apparent, however, that this condition causes a substantial health burden in men also, and that its assessment and management must ultimately be addressed across both sexes. In this article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents GRADE-assessed recommendations for the diagnosis, monitoring and treatment of osteoporosis in men. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its associated high fracture risk in men, covering disease burden, appropriate interpretation of bone densitometry (including the use of a female reference database for densitometric diagnosis in men) and absolute fracture risk, thresholds for treatment, and interventions that can be used therapeutically and their health economic evaluation. Future work should specifically address the efficacy of anti-osteoporosis medications, including denosumab and bone-forming therapies.
Kokoelmat
- Avoin saatavuus [38840]